1994 and December 1997. None of the patients received any preoperative therapy. A part of the tissues of uterine cervical cancers and normal uterine cervices as controls was obtained immediately after hysterectomy and snap-frozen in liquid nitrogen to determine the levels of VEGF and its mRNA expression, and a neighbouring part of the tissues was submitted for histopathological study. The clinical staging was determined by International Federation of Obstetrics and Gynecology (FIGO) classification (FIGO News, 1989) .
Immunohistochemistry
Four-micrometer sections were cut from formalin-fixed paraffinembedded tissue with a microtome and dried overnight at 37ЊC on a silanized slide (Dako, Carpinteria, CA, USA). Samples were deparaffinized in xylene at room temperature for 80 min and washed with a graded ethanol-water mixture and then with distilled water. The samples for VEGF were soaked in a citrate buffer and then microwaved at 100ЊC for 10 min, and those for factor VIII-related antigen were treated with 0.3 µg ml Ϫ1 trypsin in a phosphate buffer at room temperature for 20 min. The protocol for DAKO LSAB2 Kit, Peroxidase (Dako) was followed for each sample. In the described procedure, rabbit anti-human VEGF antigen VEGF(147) (200 µg ml Ϫ1 , Santa Cruz, CA, USA), and rabbit anti-factor VIII-related antigen (Zymed, San Francisco, CA, USA) as the first antibodies were used at dilutions of 1:100 and 1:2 respectively. Vascular density was evaluated with microvessel counting (Maeda et al, 1996) . The addition of the first antibody was omitted in the protocol for negative controls.
Western blot analysis for human VEGF
Tissues (wet weight: 10-20 mg) were homogenized in WB-HB buffer (10 mM) Tris-HCl, pH 7.4, 150 mM sodium chloride (NaCl), 0.5% Triton X-100 and 0.2 mM phenylmethylsulphonyl fluoride) with a Polytron homogenizer (Kinematics, Lucerne, Switzerland). The protein concentration of samples was measured by the method of Bradford (Bradford, 1976) . Each sample (25 µl) containing 100 µg of protein was added to 25 µl of a sample buffer (12.5 mM Tris-HCl, pH 6.8, 2% glycerol, 0.4% sodium dodecyl sulphate (SDS) and 1.25% 2-mercaptoethanol) and analysed by 7.5% SDS polyacrylamide gel electrophoresis (SDS-PAGE) under nonreducing conditions. The gel was transferred to a nitrocellulose membrane (Hybond ECL Western; Amersham, Arlington Heights, IL, USA). The membrane was blocked with 5% milk (from dehydrate) in a blocking buffer (20 mM Tris-HCl, pH 7.6, 137 mM NaCl and 0.1% Tween-20), incubated with rabbit anti-human VEGF antibody (1:1000) (Oncogene Research Products, Cambridge, MA, USA), washed, and then incubated with peroxidase-linked speciesspecific whole antibody, anti-rabbit immunoglobulin from donkey (1:2000) (Amersham, Buckinghamshire, UK). Specific bands were detected with electrochemiluminescence (ECL) reagent (Amersham, Arlington Heights, IL, USA), and X-ray film was exposed on the membrane at room temperature for 10 min. 
Enzyme immunoassay for determination of human VEGF antigen
All steps were carried out at 4ЊC. Tissues (wet weight: 10-20 mg) were homogenized in HG buffer (5 mM Tris-HCl, pH 7.4, 5 mM NaCl, 1 mM calcium chloride, 2 mM ethyleneglycol-bis-[β-
aminoethyl ether]-N,N,N′,N′-tetraacetic acid, 1 mM magnesium chloride (MgCl 2 ), 2 mM dithiothreitol (DTT), 25 µg ml Ϫ1 aprotinin and 25 µg ml Ϫ1 leupeptin) with a Polytron homogenizer (Kinematics). This suspension was centrifuged in a microfuge at 12 000 rpm for 3 min to remove the nuclear pellet. The protein concentration of samples was measured by the method of Bradford to standardize VEGF antigen levels (Bradford, 1976) . VEGF antigen levels in the samples were determined by a sandwich enzyme immunoassay using a Human VEGF Assay Kit-IBL (Immuno Biological Laboratories, Gunma, Japan). The levels of VEGF were standardized with the corresponding cellular protein concentrations.
RT-PCR to amplify VEGF mRNA
The oligodeoxynucleotides of specific primers in PCR were synthesized according to the published information (cDNA for VEGF (Houck et al, 1991) as shown in Figure 1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Arcari et al, 1984) ) as follows:
sense primer for VEGF mRNA: 5′-AGGCCAGCACATAG-GAGAGA-3′ (in exon 4) antisense primer for VEGF mRNA: 5′-ACCGCCTCG-GCTTGTCACAT-3′ (in exon 8) sense primer for GAPDH mRNA: 5′-TGAAGGTCGGAGT-CAACGGATTTGGT-3′ (in exon 2) antisense primer for GAPDH mRNA: 5′-CATGTGGGCCAT-GAGGTCCACCAC-3′ (in exon 8).
Total RNA was isolated from the cells by the acid guanidium thiocyanate-phenol-chloroform extraction method (Chomczynski and Sacchi, 1987) . Total RNA was reverse transcribed with Moloney murine leukaemia virus reverse transcriptase (MMLV-RTase, 200 units, Gibco BRL, Gaithersburg, MD, USA) in a buffer of 20 mM Tris-HCl, pH 8.4, 50 mM potassium chloride (KCl), 2.5 mM MgCl 2 , 0.1 mg ml Ϫ1 bovine serum albumin, 10 mM DTT and 0.5 mm deoxynucleotides to generate cDNAs using random hexamer (50 ng, Gibco BRL) at 37ЊC for 60 min. The RT reaction mixture was heated at 94ЊC for 5 min to inactivate MMLV-RTase. Ten cycles of PCR for VEGF mRNA, consisting of denaturation for 1 min at 94ЊC, annealing for 1 min at 55ЊC, and extension for 1 min at 72ЊC, were carried out with reverse transcribed cDNA, 0.1 µM specific primers and Vent DNA polymerase (New England Biolabs, Beverly, MA, USA) in a buffer of 10 mM KCl, 20 mM Tris-HCl, pH 8.8, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 0.1% Triton X-100 and 0.15 mM deoxynucleotide phosphates using the IWAKI thermal sequencer TSR-300 (Iwaki Glass, Tokyo, Japan). Additionally, 23 cycles of PCR for VEGF and GAPDH mRNAs as an internal standard were done in the same manner.
The signal intensity curve for mRNA expression is necessary for an accurate measurement of the mRNA by RT-PCR. A series of PCR templates (1.5 µg, 3 µg, 6 µg, 12 µg, 24 µg and 48 µg reverse transcribed-total RNA) were prepared to get the signal intensity curve of the mRNA levels on RT-PCR-Southern blot. The signal intensity curve for VEGF and GAPDH mRNA levels ranging from 1.5 µg to 24 µg reverse transcribed-total RNA of normal uterine cervix by RT-PCR-Southern blot was linear (Figure 2) . Therefore, semiquantative alternation of VEGF mRNA levels standardized with GAPDH mRNA levels was thought to be reliable. Additionally, the template for negative controls of RT-PCR was not reverse transcribed. The Southern blot revealed no band in the negative control for each sample (data not shown).
Southern blot analysis for quantities of VEGF mRNA expression
PCR products were applied to 1.2% agarose gel, and electrophoresis was performed at 50-100 V. PCR products were capillary-transferred to an Immobilon transfer membrane (Millipore Corp., Bedford, MA, USA) for 16 h. The membrane was dried at 80ЊC for 30 min, and was UV-irradiated to tightly fix PCR products. PCR products on the membrane were prehybridized in a buffer of 1 M NaCl, 50 mM Tris-HCl pH 7.6 and 1% SDS at 42ЊC for 1 h, and hybridized in the same solution with the biotinylated oligodeoxynucleotide probes synthesized from the sequences of VEGF and GAPDH cDNAs between the specific primers at 65ЊC overnight as follows: probe for VEGF gene: 5′-CAGCACAA-CAAATGTGAATG-3′ (in exon 4); probe for GAPDH gene: 5′-GCTCACTGGCATGGCCTTCC-3′ (in exon 8).
Specific bands hybridized with the biotinylated probes were detected with Plex Luminescent Kits (Millipore Corp.), and X-ray film was exposed on the membrane at room temperature for 10 min. The quantification of Southern blot was carried out with Bio Image (Millipore, Ann Arbor, MI, USA). The intensity of specific bands was standardized with that of GAPDH mRNA.
Statistics
The levels of VEGF and its mRNA were measured from three parts of the same tissue in triplicate. Statistical analysis was performed with Student's t-test; differences were considered significant when P was less than 0.05.
RESULTS
Immunohistochemical staining for VEGF (n ϭ 120) was carried out to study VEGF localization in the tumours, and the strength of staining was correlated with VEGF levels measured by a sandwich enzyme immunoassay. As shown in Figure 3 , positive staining is seen dominantly in the cytoplasm of the cancer cells, and faintly in interstitial cells. The intensity of VEGF staining was significantly stronger in adenocarcinomas than in squamous cell carcinomas. There was a significant correlation between VEGF levels and microvessel count, as shown in Figure 4 (y ϭ 0.034 x ϩ 9.049, r ϭ 0.64.)
To analyse which subtypes of VEGF (as shown in Figure 5 ) induce angiogenesis, the following studies were carried out. In (FIGO News, 1989) uterine cervical cancers and normal uterine cervices, mainly VEGF 165 and VEGF 121 and their mRNAs were detected by Western blot and RT-PCR-Southern blot respectively. VEGF 189 and its mRNA were only remarkably faintly detected, and VEGF 206 and its mRNA were not detected. The two main subtypes and their mRNAs expressed in uterine cervical cancers and normal uterine cervices are shown in parallel in Figure 5 . The simultaneous determinations of total VEGF level by a sandwich enzyme immunoassay and subtype mRNAs with RT-PCR-Southern blot is believed to provide enough information to reliably identify the population of subtype protein expressions.
Among the four subtypes of VEGF, the populations of VEGF 165 and VEGF 121 were dominant in normal uterine cervices and uterine cervical cancers. There was no significant difference in the levels of VEGF, and VEGF 165 and VEGF 121 mRNAs among normal uterine cervices and uterine cervical cancers classified according to histological types. However, they were remarkably higher in some adenocarcinomas of the cervix than in other cases, including normal cervices ( Figure 6 ). Similarly, there was no significant difference in their levels among normal uterine cervices and uterine cervical cancers classified according to clinical stages. However, their levels were remarkably higher in some stages II and III/IV adenocarcinomas of the cervix than in other cases, including normal cervices (Figure 7 ).
DISCUSSION
Newly developed capillary network formation from the original vessel is designated as neovascularization. Generally, turnover of capillary endothelial cells is extremely slow, to the order of months or years in physiological neovascularization, while the turnover in ovary and uterine endometrium is rapidly altered along with ovarian cycle. The turnover with malignant transformation becomes rapid, which might contribute to the acceleration of tumour growth (Denekamp, 1984) . Expression of the tumour cell-derived angiogenic factors, bFGF, VEGF, PD-ECGF and IL-8, may be specific for each tumour and dependent on the process of tumour growth and spreading. The levels of bFGF and its mRNA were higher in advanced primary uterine cervical cancers, regardless of histological type (Fujimoto et al, 1997) . The levels of PD-ECGF and its mRNA were higher and in a wider range in uterine cervical cancers, especially squamous cell carcinomas, regardless of clinical stage (Fujimoto et al, 1999) . VEGF, secreted from many tumours, does not contribute to tumour growth via an autocrine pathway to tumour cells, but via a paracrine pathway to surrounding microvessels (Berkman et al, 1993) . Furthermore, it facilitates metastasis via neovascularization (Warren et al, 1995) . In the present study, it is demonstrated that VEGF dominantly expresses in the cancer cells, and VEGF levels correlate to microvessel density in uterine cervical cancers.
Among VEGF subtypes, VEGF 189 is closely associated with progression of non-small-cell lung cancer . Coexpression of VEGF 121 , VEGF 165 and especially VEGF 189 was correlated with liver metastasis and poor prognosis in colon cancer . Only VEGF 165 protein was detected in normal and malignant breast tissues (Scott et al, 1998) . VEGF 165 was elevated in all stages of ovarian carcinoma via angiogenic activity (Fujimoto et al, 1998a) . Intracerebral tumour-associated haemorrhage was caused by overexpression of VEGF 121 and VEGF 165 but not VEGF 189 (Cheng et al, 1997) . VEGF 165 and VEGF 121 in some uterine endometrial cancers contribute to the early process of advancing of malignancy via angiogenic activity (Fujimoto et al, 1998b) . In the present study, the populations of VEGF 165 and VEGF 121 were dominant in uterine cervical cancers. VEGF 145 expression was demonstrated in several cell lines derived from the female reproductive system, and might contribute unique biological properties distinct from those of previously characterized VEGF isoforms (Poltorak et al, 1997) . We noticed that in approximately 10% of cases the band of VEGF 165 was relatively thick, and might involve the isoform VEGF 145 . However, in uterine cervical cancers, the dominant expressed isoforms were definitely VEGF 165 and VEGF 121 . Therefore, the manner of VEGF subtype expression might depend upon tissue specificity, and the levels of VEGF 165 and VEGF 121 might be essential to total angiogenic activity supplied from VEGFs. The levels of VEGF and VEGF 165 and VEGF 121 mRNAs were higher in some relatively advanced adenocarcinomas of the cervix. Therefore, the elevation of VEGF 165 and VEGF 121 might contribute to the relatively late advancing via angiogenic activity in some adenocarcinomas of the cervix. This indicates that angiogenic inhibitors (Folkman and Ingber, 1987; Fujimoto et al, 1989; Ingber et al, 1990 ) on the new capillary formation might be effective as therapy for some adenocarcinomas of the cervix apart from a direct anti-tumoural effect on cancer cells.
